GSA Capital Partners’s Milestone Pharmaceuticals MIST Stock Holding History

GSA Capital Partners’s Portfolio MIST Stock Details MIST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-26,893	Closed	-$32K	–	2001
2026 Q1	$32K	Sell	26,893 -209,245	-89%	-$366K	﹤0.01%	1627
2025 Q4	$477K	Buy	236,138 +157,391	+200%	+$339K	0.04%	842
2025 Q3	$157K	Buy	+78,747	New	+$138K	0.01%	1475
2023 Q4	–	Sell	-48,796	Closed	-$151K	–	1755
2023 Q3	$151K	Sell	48,796 -17,544	-26%	-$54.5K	0.01%	1339
2023 Q2	$189K	Sell	66,340 -33,428	-34%	-$126K	0.02%	1290
2023 Q1	$393K	Buy	+99,768	New	+$365K	0.04%	862

Other funds holding MIST

PCM

Pavaki Capital Management Pueblo, Colorado $287M AUM

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

PBM

Propel Bio Management Los Angeles, California $191M AUM 102.42% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

SAM

Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

KCM

Kalehua Capital Management Dallas, Texas $174M AUM

LPC

Lion Point Capital New York $20.9M AUM 195.52% 1-Year Est. Return

GSA Capital Partners's MIST Position: Q2 2026 in Review

GSA Capital Partners sold out of Milestone Pharmaceuticals (MIST) in Q2 2026, closing a stake of 26,893 shares — an estimated $32K sold.

GSA Capital Partners first reported a position in MIST in Q1 2023 and held it in 6 quarters. The position peaked at $477K in Q4 2025. 78 funds tracked by Wall St. Rank hold MIST as of Q2 2026.

GSA Capital Partners reported no remaining Milestone Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
GSA Capital Partners sold 26,893 Milestone Pharmaceuticals shares in Q2 2026, an estimated $32K.
GSA Capital Partners first reported a position in Milestone Pharmaceuticals in Q1 2023 and held it in 6 quarters.
GSA Capital Partners's Milestone Pharmaceuticals position peaked at $477K in Q4 2025.
78 funds tracked by Wall St. Rank held Milestone Pharmaceuticals as of Q2 2026.

Based on GSA Capital Partners's 13F filing for Q2 2026, filed 6 Aug 2026.